Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
Source: SeekingAlpha
2026-03-05 00:42:17 ET
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer March 4, 2026 5:30 PM EST...
Read the full article on Seeking Alpha
For further details see:
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
Telix Pharmaceuticals Limited
NASDAQ: TLX
TLX Trading
-3.46% G/L:
$7.26 Last:
25,890 Volume:
$7.31 Open:
TLX Latest News
February 27, 2026 07:00:00 am
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
February 26, 2026 05:35:00 am
1 Basically Unknown Stock That Could Turn Cancer?Imaging Breakthroughs Into Generational Wealth
TLX Stock Data
$2,423,405,271
305,469,565
N/A
8
N/A
Biotechnology & Life Sciences
Healthcare
US
Victoria
